Session Type: ACR Poster Session C
Session Time: 9:00AM-11:00AM
Background/Purpose: Predictors of rheumatoid arthritis (RA) response to anti-TNF agents have been described. Except for certolizumab, the value of interim analysis before 24 weeks of treatment is not clear to predict response. The purpose of this observational study was to evaluate predictors of response of anti-TNF agents in RA patients in a real-life situation tertiary center.
Methods: An inception cohort of all RA patients (ACR 1987) who received the first anti-TNF dose in the rheumatology outpatient infusion center between July, 2007 and July, 2012 was analyzed. Demographic, clinical and laboratorial data, including disease activity score (DAS28) were recorded at baseline and each 6-8 weeks and at each therapeutic change or interruption. Drug response at 24 weeks was evaluated. Remission was defined as DAS28 was ≤ 2.6 at 24 weeks. Drug survival was also analyzed. Baseline data, early (6-8 weeks) and late (14-16 weeks) significant (≥0.6) and very significant (≥1.2) changes in DAS28 were evaluated in order to predict remission at 24 weeks. Any cycle of anti-TNF was included.
Results: One hundred sixty-six RA patients were included, corresponding to 215 cycles of anti-TNF treatments. Patients were predominantly female (n= 91%;n=151); and had a positive rheumatoid factor (RF) (80%; n=133). Mean age and mean disease duration: 49.2 ± 12.2 and 12.5 ±
Conclusion: The low and not sustained remission rate, regardless of the anti-TNF treatment, with short drug survival, shows the actual difficulties in treating RA in a real-life setting. Interim positive and negative significant variations in disease activity before 24 weeks of treatment can help to avoid prolonged and unnecessary exposition to such drugs.
To cite this abstract in AMA style:Ribeiro ACM, Bonfiglioli K, Miossi R, Saad CGS, Moraes JCB, Waisberg MG, de Souza FHC, Aikawa NE, do Prado LL, Lopes M, Seguro L, Bonfá E. Early DAS28 Drop Is a Predictor for Clinical Response to Anti-TNF Agents in Patients with Rheumatoid Arthritis: An Observational Study of a Real Life Inception Cohort [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/early-das28-drop-is-a-predictor-for-clinical-response-to-anti-tnf-agents-in-patients-with-rheumatoid-arthritis-an-observational-study-of-a-real-life-inception-cohort/. Accessed December 2, 2020.
« Back to 2016 ACR/ARHP Annual Meeting
ACR Meeting Abstracts - https://acrabstracts.org/abstract/early-das28-drop-is-a-predictor-for-clinical-response-to-anti-tnf-agents-in-patients-with-rheumatoid-arthritis-an-observational-study-of-a-real-life-inception-cohort/